Clinical trial
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety…
NCT00458042 · United Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00458042 |
|---|---|
| Title | Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction |
| Official title | Transitioning To Intravenous Remodulin® (Treprostinil Sodium) From Inhaled Iloprost (Ventavis®) in Patients With Pulmonary Arterial Hypertension: Safety, Efficacy and Treatment Satisfaction |
| Lead sponsor | United Therapeutics, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension, Pulmonary |
| Intervention type | Drug |
| Interventions | treprostinil sodium |
| Enrollment | 10 |
| Start date | Mar 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Apr 9, 2007 |
| Last update posted | Nov 12, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: